Glutaminyl Cyclase, Diseases, and Development of Glutaminyl

Por um escritor misterioso

Last updated 13 fevereiro 2025

Glutaminyl Cyclase, Diseases, and Development of Glutaminyl

Upregulation of Glutaminyl Cyclase Contributes to ERS-Induced Apoptosis in PC12 Cells

Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer's Agents by Structure-Based Design

Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design - ScienceDirect

Upregulation of Glutaminyl Cyclase Contributes to ERS-Induced Apoptosis in PC12 Cells

Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors

Therapeutic potential of glutaminyl cyclases: Current status and emerging trends - ScienceDirect

RU2662559C1 - New inhibitor of glutaminyl cyclase and its use for treatment of lung and respiratory diseases - Google Patents

Upregulation of Glutaminyl Cyclase Contributes to ERS-Induced Apoptosis in PC12 Cells

PDF) Preparation of imidazolyl thiourea derivs. as glutaminyl cyclase inhibitors for treating cancer, nervous system disorders, and other diseases

Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors

Schematic drawing of QC inhibitor approach. pGlu-Aβ

Computational Methods for the Design and Development of Glutaminyl Cyclase Inhibitors in Alzheimer's Disease

Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology

Recomendado para você